

Registration 7:30-8:15

Welcome address 8:15-8:30

Plenary lecture 8:30-9:15

Dr Franck Pagès HEGP Paris

Immunescore and immune modulation of cancer

Symposium Basic science in adrenocortical cancer 9:15-11:00

-Enzo Lalli, IPMC, Nice

New markers of malignancy in ACC

-Antonio Lerario, University of Michigan, Ann Arbor

The role of G0S2 in ACC

-Nadia Cherradi, CEA, Grenoble

The role of microRNAs in adrenocortical cancer pathogenesis

-Alexandre Boyer, University of Montreal

Hippo signalling in adrenal physiology

-Selected from abstracts

Coffee break 11:00-11:30

Symposium Genetics of Adrenal tumors 11:30-13:15

-Electron Kebebew, Stanford

Translating metastatic ACC OMICS analyses to new therapies

-Emilia Pinto, St Jude Children's Hospital

A novel gene influencing development of ACC

-Gareth Bond, Ludwig Institute for Cancer Research, Oxford

Genetic determinants of onset of ACC

-Bill Rainey, University of Michigan, Ann Arbor

Novel driver genes in aldosterone producing adenomas

-Selected from abstracts

Lunch break 13:15-14:30

Symposium Animal models of adrenal diseases 14:30-16:15

-Constanze Hantel, University Hospital, Zürich

An update on preclinical models of ACC

-Katie Basham, University of Michigan, Ann Arbor

ZNRF3 in adrenal differentiation and disease

-Pierre Val, GReD, Clermont-Ferrand

ZNRF3 and P53 in ACC development

-Amanda Swain, Institute of Cancer Research, London

HOXB9 and WNT signaling in adrenal tumors development

-Selected from abstracts

Coffee break 16:15-16:45

WNT signaling in ACC and beyond 16:45-18:30

-Sining Leng, Harvard

Activating beta-catenin mutations and P53 in ACC

-Andreas Schedl, iBV, Nice

Overexpression of Rspodins in mouse models of adrenal tumorigenesis

-Emmanuelle Szenker-Ravi, A*STAR, Singapore

Rspodins act independently of Lgr4/5/6 in limb development

- Madelon Maurice, UMC Utrecht
RNF43 mutations in cancer
- Selected from abstracts

Gala Diner at Hôtel Littéraire Alexandre Vialatte 20:30-23:00

28th September

Symposium Management & prognostic factors in ACC 8:30-10:15

- Wiebke Arlt, University of Birmingham
Metabolomics of ACC
- Martin Fassnacht, University Hospital Würzburg
Guidelines on the treatment of ACC (ESE 2018)
- Peter Igaz, Semmelweis University, Budapest
Circulating microRNAs for the diagnosis of adrenocortical tumors
- Tom Giordano, University of Michigan, Ann Arbor
Adrenal cortical tumours: diagnostic and prognostic update
- Barbara Miller, University of Michigan, Ann Arbor
Surgery of ACC

Coffee break 10:15-10:45

Symposium ACC treatment 10:45-12:30

- Gary Hammer, University of Michigan, Ann Arbor
OMICS of IGF responders
- Eric Baudin, IGR, Paris
To be determined
- Massimo Terzolo, Università Degli Studi, Torino
Adiuvato 1
- Mouhammed Habra, MD Anderson
Adiuvato 2
- Selected from abstracts

Lunch break 12:30-13:30

Guided tour of posters 13:30-15:00

Symposium Novel approaches in ACC treatment 15:00-16:45

- Matthias Kroiss, University Hospital Würzburg
Is there a preclinical rationale to treat ACC with immunotherapy?
- Bonald Figueiredo, Instituto de Pelisa Pelé Pequeno Principe, Sao Paulo
Is ACC eligible for therapeutic vaccine?
- Ségolène Hescot, Institut Curie, Paris
Immunotherapy in ACC : where do we stand ?
- Cédric Malicet, Vect Horus, Marseille
targeting of adrenal tumours through LDLR
- Selected from abstracts

Coffee break 16:45-17:15

Symposium Future directions in ACC research 17:15-18:15

- Guillaume Assié, Institut Cochin, Paris
The future for ACC omic markers
- Cristina Ronchi, University of Birmingham
Single cell sequencing in ACC
- Gweneg Kerdivel, Institut Cochin, Paris

Investigating epigenetic changes in adrenocortical carcinoma

Round Table on clinical trials/ACC treatment 18:15-19:00

End of Meeting – Closing remarks